OP
BMY.RT

Omni Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Omni Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-422,001
Closed -$291K – 367
2020
Q4 		$291K Buy
422,001
+98,272
+30% +$209K 0.02% 167
2020
Q3 		$728K Sell
323,729
-34,704
-10% -$99.1K 0.05% 109
2020
Q2 		$1.28M Buy
358,433
+19,904
+6% +$71.8K 0.15% 50
2020
Q1 		$1.29M Sell
338,529
-243,175
-42% -$801K 0.11% 56
2019
Q4 		$1.75K Buy
+581,704
New +$1.51M 0.05% 37

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Omni Partners's BMY.RT Position: Q1 2021 in Review

Omni Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 422,001 shares — an estimated $291K sold.

Omni Partners first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.29M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Omni Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Omni Partners sold 422,001 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $291K.
  • Omni Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Omni Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.29M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.